Empire Genomics is a clinical molecular diagnostics company. We offer a comprehensive menu of products and services that are used in guiding precise treatments for patients. We work with our clinical, research and biopharmaceutical clients to create innovative and custom solutions to make personalized medicine a reality.
Empire Genomics was founded in 2006 by Dr. Norma J. Nowak from research started at the prestigious Roswell Park Cancer Institute in Buffalo, New York. The company has developed significant expertise in genomic research, developing custom assays and high-throughput technologies to enable genome-wide analyses.
Empire Genomics is a rapidly growing and evolving company. Here are some of the major milestones in our company's history.
Empire Genomics Timeline
Graduate student Norma Nowak participates on the PSA test development team at Roswell Park Cancer Institute (RPCI).
Dr. Norma Nowak and a team at RPCI contribute to the Human Genome Project (completed in 2003).
Empire Genomics is founded with the mission of enabling personalized medicine.
Empire Genomics expands to a new location.
Empire Genomics develops the first test to predict drug response in Multiple Myeloma.
Empire Genomics develops the Neuroendocrine Prostate Cancer (NEPC) Test and launches PGx service line.
Empire Genomics receives CLIA certification, launches clinical lab, and acquired ID Labs.
Empire Genomics receives CAP certification and launches SwiftFISH Rapid Hybridization Buffer.
Commitment to Our Community
At Empire Genomics, we are committed to personalized medicine and patient care, but also to our community and to our youth. We show this support through several initiatives, including our Imperial Scholars Fellowship Training Program and our Annual Tee It Up for STEM Fundraiser.